139,015 Shares in Kenvue Inc. $KVUE Bought by Osmosis Investment Management UK Ltd

Key Points

• Osmosis Investment Management UK Ltd. acquired 139,015 Kenvue shares worth approximately $2.66 million in the second quarter. Institutional investors collectively own 97.64% of the company.
• Kenvue reported quarterly revenue of $3.96 billion and EPS of $0.31, slightly below analyst expectations, while revenue increased 3% year over year.
• The company declared a quarterly dividend of $0.21 per share, equal to an annualized $0.84 payout and a 4.4% yield. Analysts maintain a consensus “Hold” rating with an average price target of $19.27.

Osmosis Investment Management UK Ltd acquired a new position in Kenvue Inc. (NYSE:KVUE - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 139,015 shares of the company's stock, valued at approximately $2,657,000.

A number of other institutional investors have also recently bought and sold shares of the business. Johnson Financial Group Inc. bought a new position in Kenvue during the second quarter valued at about $26,000. CoreCap Advisors LLC boosted its stake in Kenvue by 64.9% in the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company's stock valued at $29,000 after acquiring an additional 591 shares during the last quarter. Elyxium Wealth LLC purchased a new position in Kenvue in the fourth quarter valued at about $26,000. Physician Wealth Advisors Inc. grew its position in shares of Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company's stock valued at $26,000 after acquiring an additional 618 shares during the period. Finally, MV Capital Management Inc. bought a new position in shares of Kenvue during the 4th quarter valued at approximately $28,000. Institutional investors own 97.64% of the company's stock.

Kenvue Stock Up 0.1%

Kenvue stock opened at $19.08 on Monday. The firm has a 50 day simple moving average of $19.05 and a 200 day simple moving average of $18.20. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $21.78. The firm has a market capitalization of $36.65 billion, a price-to-earnings ratio of 21.93, a P/E/G ratio of 1.36 and a beta of 0.47.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). The company had revenue of $3.96 billion for the quarter, compared to analysts' expectations of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The company's revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.29 EPS. On average, analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be issued a dividend of $0.21 per share. This is a positive change from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Wednesday, August 12th. This represents a $0.84 dividend on an annualized basis and a yield of 4.4%. Kenvue's payout ratio is currently 96.55%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on KVUE shares. UBS Group lowered their price target on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating on the stock in a report on Tuesday, August 11th. Barclays increased their price objective on Kenvue from $18.00 to $19.00 and gave the company an "equal weight" rating in a report on Tuesday, July 21st. Wall Street Zen downgraded Kenvue from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Weiss Ratings upgraded Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, June 15th. Finally, Zacks Research cut Kenvue from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $19.27.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source